BioIVT, a biological specimens and services firm, has snapped up Sekisui Chemical's CRO division XenoTech for an undisclosed price.
XenoTech, which Japan’s Sekisui bought in 2008, specializes in testing potential therapeutic candidates for toxicity, pharmacokinetics and drug-drug interactions. The company will continue operations from its headquarters in Kansas City. Financial details of the acquisition weren’t disclosed.
With the deal, BioIVT gets XenoTech’s product lines such as its best-in-class microsomes, which complement its own portfolio of hepatocytes and other hepatic products, BioIVT said in a Sept. 12 release.
The pairing is also expected to play to BioIVT's strengths in drug transporter research, its B-CLEAR disposition studies of biliary efflux, its HEPATOPAC long-term hepatic metabolism models and other proprietary methodologies, the company said.
“The XenoTech and BioIVT product portfolios are complementary, and when combined, will enable smarter science and accelerate medical breakthroughs that enhance and extend lives by delivering personalized biospecimen solutions to life science and diagnostic industries,” BioIVT CEO Richard Haigh in the release.